Compare CLPT & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLPT | LYEL |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | 161 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.6M | 556.1M |
| IPO Year | 2009 | 2021 |
| Metric | CLPT | LYEL |
|---|---|---|
| Price | $10.50 | $23.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $20.00 | ★ $30.60 |
| AVG Volume (30 Days) | ★ 632.0K | 74.3K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $36,971,000.00 | $36,000.00 |
| Revenue This Year | $45.67 | N/A |
| Revenue Next Year | $19.51 | $16,285.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.78 | N/A |
| 52 Week Low | $8.27 | $0.39 |
| 52 Week High | $30.10 | $45.00 |
| Indicator | CLPT | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 54.90 | 55.08 |
| Support Level | $10.02 | $21.27 |
| Resistance Level | $11.74 | $27.30 |
| Average True Range (ATR) | 0.54 | 1.71 |
| MACD | 0.29 | 0.43 |
| Stochastic Oscillator | 90.32 | 74.68 |
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.